ATE279210T1 - Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel - Google Patents

Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel

Info

Publication number
ATE279210T1
ATE279210T1 AT99928071T AT99928071T ATE279210T1 AT E279210 T1 ATE279210 T1 AT E279210T1 AT 99928071 T AT99928071 T AT 99928071T AT 99928071 T AT99928071 T AT 99928071T AT E279210 T1 ATE279210 T1 AT E279210T1
Authority
AT
Austria
Prior art keywords
cytotoxic
system containing
antineoplastic agent
releasing system
drug releasing
Prior art date
Application number
AT99928071T
Other languages
English (en)
Inventor
Peter Martin Fischer
Shudong Wang
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE279210T1 publication Critical patent/ATE279210T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Refuse Collection And Transfer (AREA)
  • Threshing Machine Elements (AREA)
AT99928071T 1998-07-03 1999-06-22 Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel ATE279210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814527.9A GB9814527D0 (en) 1998-07-03 1998-07-03 Delivery system
PCT/GB1999/001957 WO2000001417A1 (en) 1998-07-03 1999-06-22 Delivery system

Publications (1)

Publication Number Publication Date
ATE279210T1 true ATE279210T1 (de) 2004-10-15

Family

ID=10834959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928071T ATE279210T1 (de) 1998-07-03 1999-06-22 Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel

Country Status (13)

Country Link
US (2) US6472507B1 (de)
EP (1) EP1093383B1 (de)
JP (1) JP2002519392A (de)
AT (1) ATE279210T1 (de)
AU (1) AU756014B2 (de)
CA (1) CA2333145C (de)
DE (1) DE69921138T2 (de)
DK (1) DK1093383T3 (de)
ES (1) ES2230860T3 (de)
GB (2) GB9814527D0 (de)
HU (1) HUP0300246A3 (de)
IL (1) IL140650A0 (de)
WO (1) WO2000001417A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
ES2318906T3 (es) 1998-11-13 2009-05-01 Cyclacel Limited Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia.
EP1140202A1 (de) 1998-12-24 2001-10-10 Ucb S.A. Peptidischen verbindung, verfahren und verwendung
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
FR2816845B1 (fr) 2000-11-20 2006-10-20 Centre Nat Rech Scient Vecteurs de transport a travers un epithelium a jonctions serrees
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
US20050181474A1 (en) * 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
FR2849603B1 (fr) * 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US8709998B2 (en) * 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
EP1635866A2 (de) * 2003-05-20 2006-03-22 Cellpep S.A. Modifizierte antivirale peptide mit erhöhter aktivität und zellmembran-affinität
US7458683B2 (en) 2003-06-16 2008-12-02 Amo Manufacturing Usa, Llc Methods and devices for registering optical measurement datasets of an optical system
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
AU2004270251B2 (en) * 2003-09-05 2011-03-31 The General Hospital Corporation Polyacetal drug conjugates as release system
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005040193A2 (en) * 2003-10-20 2005-05-06 The Regent Of The University Of California Synthetic peptides that cause f-actin bundling and block actin depolymerization
US20050209147A1 (en) * 2004-01-16 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of RhoA signaling
WO2006029028A2 (en) * 2004-09-02 2006-03-16 Cognosci, Inc. Improved apo e analogs and methods for their use
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
MX2007010113A (es) 2005-02-18 2007-12-07 Angiochem Inc Polipeptidos de aprotinina para transportar un compuesto a traves de la barrera hematoencefalica.
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
EP1998809B1 (de) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Konjugate von camptothecin und zelldurchdringenden peptiden und deren pharmazeutische zusammensetzungen.
BRPI0709447A2 (pt) * 2006-03-30 2011-07-12 Diatos Sa conjugado, composição farmacêutica, uso e composto
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP2252314B1 (de) 2008-02-27 2014-04-09 Temple University - Of The Commonwealth System of Higher Education Leptin-agonist und anwendungsverfahren
CA2716565C (en) 2008-02-28 2017-09-12 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
JP5542804B2 (ja) 2008-05-23 2014-07-09 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア リポソームナノ粒子中で使用するための修飾薬物
EP2350118B1 (de) 2008-09-19 2016-03-30 Nektar Therapeutics Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (de) 2008-12-17 2012-08-29 Angiochem Inc Membrantyp-1-matrixmetalloproteinase-inhibitoren und ihre verwendung
FR2941230B1 (fr) 2009-01-19 2011-03-18 Centre Nat Rech Scient Polypeptides d'adressage specifique a des cellules-cibles d'otx2
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
US8501242B2 (en) 2009-05-29 2013-08-06 University Of Florida Research Foundation Methods and compositions for treating neoplasia
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
GB201001602D0 (en) 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
JP5757497B2 (ja) * 2010-10-06 2015-07-29 公立大学法人大阪府立大学 シガトキシン類ctx1bおよび54−デオキシ−ctx1bを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット
JP6258202B2 (ja) * 2011-09-08 2018-01-10 ウェスタン ユニバーシティ オブ ヘルス サイエンス がん療法における標的リポソーム
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
GB201318954D0 (en) * 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
ES2903448T3 (es) 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
EP3307326B9 (de) 2015-06-15 2021-02-24 Angiochem Inc. Verfahren zur behandlung von leptomeningealer karzinomatose
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN106937529B (zh) 2015-10-27 2021-02-05 加州太平洋医疗中心 鬼臼毒素衍生物及其应用
WO2018085836A1 (en) 2016-11-07 2018-05-11 Colorado State University Research Foundation Anti-hiv peptides
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
CN110563739A (zh) * 2018-06-05 2019-12-13 薪火炙药(北京)科技有限公司 具有选择性抗肺癌作用的鬼臼毒素类化合物p-x及其制备方法和应用
GB201915454D0 (en) 2019-10-24 2019-12-11 Norwegian Univ Sci & Tech Ntnu Antibacterial bone cement and uses thereof
KR102397922B1 (ko) * 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도
GB202006699D0 (en) 2020-05-06 2020-06-17 Therapim Pty Ltd Dosage regimen
GB202008888D0 (en) 2020-06-11 2020-07-29 Norwegian Univ Of Science And Technology (Ntnu) Peptides for sepsis treatment
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3836971C1 (de) * 1988-10-31 1990-05-17 Weck, Wolfgang, Dr.Med., 6990 Bad Mergentheim, De
US5888762A (en) * 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
EP0751225B1 (de) 1990-10-15 2001-03-28 Tecnogen S.C.P.A. Verfahren zur Feststellung von proteolitischen Wirkungen und/oder deren Inhibitoren
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
AU739028B2 (en) * 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5929042A (en) 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US5823345A (en) * 1997-07-24 1998-10-20 Berry Plastics Corporation Stackable receptacle assembly for pourable products
AU741546B2 (en) * 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system

Also Published As

Publication number Publication date
IL140650A0 (en) 2002-02-10
EP1093383A1 (de) 2001-04-25
US20030119735A1 (en) 2003-06-26
DE69921138T2 (de) 2005-11-24
US6992169B2 (en) 2006-01-31
GB2340121A (en) 2000-02-16
WO2000001417A1 (en) 2000-01-13
GB2340121B (en) 2000-09-06
GB9814527D0 (en) 1998-09-02
CA2333145A1 (en) 2000-01-13
ES2230860T3 (es) 2005-05-01
HUP0300246A3 (en) 2005-09-28
US6472507B1 (en) 2002-10-29
GB9914577D0 (en) 1999-08-25
HUP0300246A2 (en) 2003-05-28
EP1093383B1 (de) 2004-10-13
DK1093383T3 (da) 2005-02-14
DE69921138D1 (de) 2004-11-18
JP2002519392A (ja) 2002-07-02
AU4519899A (en) 2000-01-24
CA2333145C (en) 2008-03-25
AU756014B2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
EE200000380A (et) 11ß-halogeno-7(alfa)-asendatud östratrieenid, neid 11ß-halogeno-7(alfa)-asendatud östratrieene sisaldavate farmatseutiliste preparaatide valmistamise meetodid ja nende kasutamine ravimite valmistamiseks
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
EP1015008A4 (de) Verbindungen und zusammensetzungen zur administration aktiver stoffe
EP0902789A4 (de)
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
BG106151A (en) Pharmaceutical complex
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
DE59813300D1 (de) Pharmazeutische zubereitungen
ATE257377T1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
UA22792A (uk) Гомеопатичний лікарський засіб " фарингол - arn "
HUP9701598A2 (hu) Gyógyszerkészítmény
CA2458872A1 (en) Human ubiquitin-conjugating enzyme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1093383

Country of ref document: EP

REN Ceased due to non-payment of the annual fee